Pneumotox » Drug » Polyethylene glycol (PEG)

Polyethylene glycol (PEG)

2

Last update : 24/04/2023

I.ao Pulmonary infiltrates

1

II.a Pulmonary edema, noncardiogenic (NCPE)

1

II.b ARDS - Acute lung injury

1

II.q Respiratory distress or failure, not otherwise specified

1

IV.a Bronchospasm - Wheezing - Asthma

1

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

1

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

1

XI.g Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

1

XIX.f BAL: Foamy macrophages

1

XIX.i BAL: Oil red O-stainable material in BAL macrophages othen than exogenous lipids

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist